TY - JOUR
T1 - The exposome and liver disease - how environmental factors affect liver health
AU - Barouki, Robert
AU - Samson, Michel
AU - Blanc, Etienne B.
AU - Colombo, Massimo
AU - Zucman-Rossi, Jessica
AU - Lazaridis, Konstantinos N.
AU - Miller, Gary W.
AU - Coumoul, Xavier
N1 - Funding Information:
This work was supported by NIH RC2 DK 118619 and R01 DK126691 (to KNL and GWM) and U2C ES030163 (to GWM) and by recurrent funding from Université Paris Cité and Inserm unit 1124.
Publisher Copyright:
© 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - Since the initial development of the exposome concept, much effort has been devoted to the characterisation of the exposome through analytical, epidemiological, and toxicological/mechanistic studies. There is now an urgent need to link the exposome to human diseases and to include exposomics in the characterisation of environment-linked pathologies together with genomics and other omics. Liver diseases are particularly well suited for such studies since major functions of the liver include the detection, detoxification, and elimination of xenobiotics, as well as inflammatory responses. It is well known that several liver diseases are associated with i) addictive behaviours such as alcohol consumption, smoking, and to a certain extent dietary imbalance and obesity, ii) viral and parasitic infections, and iii) exposure to toxins and occupational chemicals. Recent studies indicated that environmental exposures were also significantly associated with liver diseases, and these include air pollution (particulate matter and volatile chemicals), contaminants such as polyaromatic hydrocarbons, bisphenol A and per-and poly-fluorinated substances, and physical stressors such as radiation. Furthermore, microbial metabolites and the “gut-liver” axis play a major role in liver diseases. Exposomics is poised to play a major role in the field of liver pathology. Methodological advances such as the exposomics-metabolomics framework, the determination of risk factors’ genomic and epigenomic signatures, and cross-species biological pathway analysis should further delineate the impact of the exposome on the liver, opening the way for improved prevention, as well as the identification of new biomarkers of exposure and effects, and additional therapeutic targets.
AB - Since the initial development of the exposome concept, much effort has been devoted to the characterisation of the exposome through analytical, epidemiological, and toxicological/mechanistic studies. There is now an urgent need to link the exposome to human diseases and to include exposomics in the characterisation of environment-linked pathologies together with genomics and other omics. Liver diseases are particularly well suited for such studies since major functions of the liver include the detection, detoxification, and elimination of xenobiotics, as well as inflammatory responses. It is well known that several liver diseases are associated with i) addictive behaviours such as alcohol consumption, smoking, and to a certain extent dietary imbalance and obesity, ii) viral and parasitic infections, and iii) exposure to toxins and occupational chemicals. Recent studies indicated that environmental exposures were also significantly associated with liver diseases, and these include air pollution (particulate matter and volatile chemicals), contaminants such as polyaromatic hydrocarbons, bisphenol A and per-and poly-fluorinated substances, and physical stressors such as radiation. Furthermore, microbial metabolites and the “gut-liver” axis play a major role in liver diseases. Exposomics is poised to play a major role in the field of liver pathology. Methodological advances such as the exposomics-metabolomics framework, the determination of risk factors’ genomic and epigenomic signatures, and cross-species biological pathway analysis should further delineate the impact of the exposome on the liver, opening the way for improved prevention, as well as the identification of new biomarkers of exposure and effects, and additional therapeutic targets.
KW - biliary disease
KW - exposomics
KW - hepatocellular carcinoma
KW - MAFLD
KW - metabolomics
KW - microbiota
KW - mutational signature
KW - toxicological pathways
KW - viral hepatitis
KW - xenobiotic metabolism
UR - http://www.scopus.com/inward/record.url?scp=85153628532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153628532&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2023.02.034
DO - 10.1016/j.jhep.2023.02.034
M3 - Review article
C2 - 36889360
AN - SCOPUS:85153628532
SN - 0168-8278
JO - Journal of Hepatology
JF - Journal of Hepatology
ER -